Alendronate: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 15: | Line 15: | ||
== Structure and General Function == | == Structure and General Function == | ||
[[Image:Alendronate.gif]]<ref>Image from: http://pharmacy-and-drugs.com</ref> | [[Image:Alendronate.gif]]<ref>Image from: http://pharmacy-and-drugs.com</ref> | ||
Alendronate is an aminobisphosphonate with a nonhydrolyzable P-C-P. Alendronate generally affects the | |||
Alendronate is an aminobisphosphonate with a nonhydrolyzable P-C-P. Alendronate generally affects the activity of osteoclasts in bone. Osteoclasts are responsible for breaking down bone and also for bone resorption (losing bone substance). <ref>http://www.medterms.com/script/main/art.asp?articlekey=11794</ref> When alendronate is present, bone resorption is inhibited and bone breakdown is diminished. | |||
| Line 24: | Line 26: | ||
=== Protein-Tyrosine-Phosphatases (PTP) === | === Protein-Tyrosine-Phosphatases (PTP) === | ||
Protein-Tyrosine-Phosphatses (PTPs) are reported to have an effect on osteoclast formation and Initial reports indicated that alendronate inhibited several types of PTPs, though specific mechanisms are not known. The data does suggest that alendronate works as an antagonist, which means that, when bound, the alendronate does not elicit a response from the protein but rather disallows the binding of an agonist which would cause a change (likely activating) in the protein.<ref>http://www.drugbank.ca/drugs/DB00630</ref><ref>http://www.ncbi.nlm.nih.gov/pubmed/8610169</ref><ref>http://www.ncbi.nlm.nih.gov/pubmed/9310349</ref> A | Protein-Tyrosine-Phosphatses (PTPs) are reported to have an effect on osteoclast formation and function.<ref> | ||
<scene name='Sandbox_59/Ptpre/1'>TextToBeDisplayed</scene></ref> Initial reports indicated that alendronate inhibited several types of PTPs, though specific mechanisms are not known. The data does suggest that alendronate works as an antagonist, which means that, when bound, the alendronate does not elicit a response from the protein but rather disallows the binding of an agonist which would cause a change (likely activating) in the protein.<ref>http://www.drugbank.ca/drugs/DB00630</ref><ref>http://www.ncbi.nlm.nih.gov/pubmed/8610169</ref><ref>http://www.ncbi.nlm.nih.gov/pubmed/9310349</ref> A | |||
<scene name='Sandbox_59/Ptpre/1'>PTP example</scene> is given, so the binding site can be seen. | <scene name='Sandbox_59/Ptpre/1'>PTP example</scene> is given, so the binding site can be seen. | ||
=== Farnesyl Pyrophosphate Synthase (FPPS) === | === Farnesyl Pyrophosphate Synthase (FPPS) === | ||
<Structure load='2f92' size='450' frame='true' align='right' caption='Shown: The asymmetric subunit of FPPS, not the assumed biological molecule.' scene='Insert optional scene name here' /> | <Structure load='2f92' size='450' frame='true' align='right' caption='Shown: The asymmetric subunit of FPPS, not the assumed biological molecule.' scene='Insert optional scene name here' /> | ||
<scene name='Sandbox_59/Fpps/2'>FPPS</scene> is considered the main target protein of aminobisphosphonates (including alendronate). | <scene name='Sandbox_59/Fpps/2'>FPPS</scene> is considered the main target protein of aminobisphosphonates (including alendronate). | ||
| Line 41: | Line 43: | ||
<scene name='Sandbox_59/Fpps_bound_phosphate/2'>FPPS bound phosphate</scene> | <scene name='Sandbox_59/Fpps_bound_phosphate/2'>FPPS bound phosphate</scene> | ||
